Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünwald, Viktor, Merseburger, Axel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390993/
https://www.ncbi.nlm.nih.gov/pubmed/22787405
http://dx.doi.org/10.2147/OTT.S23273
_version_ 1782237478737936384
author Grünwald, Viktor
Merseburger, Axel S
author_facet Grünwald, Viktor
Merseburger, Axel S
author_sort Grünwald, Viktor
collection PubMed
description The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib’s efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.
format Online
Article
Text
id pubmed-3390993
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33909932012-07-11 Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Grünwald, Viktor Merseburger, Axel S Onco Targets Ther Review The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib’s efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients. Dove Medical Press 2012-06-18 /pmc/articles/PMC3390993/ /pubmed/22787405 http://dx.doi.org/10.2147/OTT.S23273 Text en © 2012 Grünwald and Merseburger, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Grünwald, Viktor
Merseburger, Axel S
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title_full Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title_fullStr Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title_full_unstemmed Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title_short Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
title_sort axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mrcc) after failure of prior systemic treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390993/
https://www.ncbi.nlm.nih.gov/pubmed/22787405
http://dx.doi.org/10.2147/OTT.S23273
work_keys_str_mv AT grunwaldviktor axitinibforthetreatmentofpatientswithadvancedmetastaticrenalcellcarcinomamrccafterfailureofpriorsystemictreatment
AT merseburgeraxels axitinibforthetreatmentofpatientswithadvancedmetastaticrenalcellcarcinomamrccafterfailureofpriorsystemictreatment

Ejemplares similares